FECAL CALPROTECTIN AND DRUG LEVELS AT WEEK 14 PREDICT LONG-TERM RESPONSE OF VEDOLIZUMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASES: A REPORT FROM THE PROSPECTIVE, MULTI-CENTRE VEDOKIDS STUDY

Zivia Shavit-Brunschwig  ¹     Oren Ledder  ¹     Gili Focht  ¹     Gila Abitbol  ¹     Darja Urlep  ²     Raffi Lev-Tzion  ²     Esther Orlanski-Meyer  ²     Efrat Broide  ³     Amit Assa  ⁴     Seamus Hussey  ⁵     Anat Yerushalmy Feler  ⁶     Arie Levine  ⁷     James Markowitz  ⁸     Marina Aloi  ⁹     Ronen Stein  ¹⁰     Dror Shouval  ¹¹     Christoph Norden  ¹²     Ron Shaoul  ¹³     Richard K Russell  ¹⁴     Dan Turner  ^14    
1 Shaare Zedek Medical Center, Jerusalem, Israel
² University Children’s Hospital, Ljubljana, Slovenia
³ Shamir Medical Center, Beer Yaakov, Israel
⁴ Schneider Children’s Medical Center, Petah Tikva, Israel
⁵ National Children’s Research Center, Dublin, Ireland
⁶ Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
⁷ Wolfson Medical Center, Holon, Israel
⁸ The Feinstein Institute for Medical Research, Northwell, Israel
⁹ Sapienza University of Rome, Rome, Italy
¹⁰ Children’s Hospital of Philadelphia, Philadelphia, United States
¹¹ Sheba Medical Center, Ramat Gan, Israel
¹² Hvidovre University Hospital, Copenhagen, Denmark
¹³ Rambam Medical Center, Haifa, Israel
¹⁴ The Royal Hospital for Children, Glasgow, United Kingdom

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)